Purification method of oligonucleotide
The problem of depurine by-products under acidic conditions is solved by using pure water from 40°C to 60°C in the purification process of oligonucleotides, and purified by reverse phase high-performance liquid chromatography or anion exchange chromatography. It achieves efficient and stable oligonucleotide purification, suitable for large-scale commercial processes.
Patent Information
- Application Number
- CN202411067299.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art During the purification process of oligonucleotides, the production of depurinated by-products under acidic conditions for a long time has led to the production of depurinated by-products. The traditional method steps are cumbersome and time-consuming, making it difficult to achieve an efficient and stable large-scale commercial process.
Tangential flow filtration was performed using pure water at 40°C to 60°C to remove the hydroxyl protecting group at the 5'-O-terminal end of the oligonucleotide, and purify it in combination with reverse phase high-performance liquid chromatography or anion exchange chromatography to avoid detachment under acidic conditions. Purine reaction and desalination and purification without introducing a neutralization step.
It realizes efficient purification of oligonucleotides, avoids the generation of depurinated by-products, simplifies the process flow, is suitable for large-scale commercial processes, and improves purification efficiency and stability.
Smart Images

Figure BDA0004979719170000081 
Figure BDA0004979719170000091 
Figure BDA0004979719170000092
Abstract
Description
Technical Field
[0001] The present invention relates to a method for purifying oligonucleotides. Background Art
[0002] Oligonucleotide can be used in multiple biological and biochemical applications.For example, oligonucleotide can be used in drug exploration and development, in diagnostic tests, as research agents (primers or probes such as polymerase chain reaction (PCR)), as antisense agents in target verification, as competitive inhibitors of transcription factors, as ribozymes, as fit-bodies, as stimulants of the immune system, or as biotherapeutic agents for the treatment of diseases.Due to the great progress made in the research of oligonucleotide drugs in recent years, increasing oligonucleotide drugs have begun to enter the clinical stage.Therefore, it is more important to develop a quick, cheap and effective method for oligonucleotides with GMP quality.
[0003] At present, oligonucleotides are usually synthesized by solid phase synthesis, and the obtained oligonucleotides still contain a large amount of impurities after being cleaved from the resin, and a hydroxyl protecting group is left at the end of the 5'-O-oligonucleotide, so it is necessary to further purify and remove the hydroxyl protecting group at the 5'-O-end. The crude oligonucleotides obtained by solid phase synthesis are usually purified using reversed phase high performance liquid chromatography (RP-HPLC) (e.g., Krotz et al., Organic Process Research & Development 2003, 7, 47-52). This traditional purification method usually includes the steps of: a) reverse phase chromatography purification; b) concentration and desalination; c) removal of the acid-labile hydroxyl protecting group at the 5'-O-end in the solution; and d) further concentration and desalination. This traditional purification method requires repeated concentration and desalination, which requires a lot of operating time. For this reason, the prior art CN112771062A improves the traditional purification method, and discloses a method for purifying oligonucleotides, including the steps of: (1) subjecting the crude oligonucleotide obtained after resin cleavage and phosphate deprotection to reverse phase high performance liquid chromatography or anion exchange chromatography; (2) removing the acid-labile 5'-hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide by tangential flow filtration with an acidic buffer solution; (3) a neutralization step, which includes neutralizing the obtained filtrate with a base by tangential flow filtration; and (4) a desalting step, which includes washing the filtrate obtained from the neutralization with water or a mixture of water and an organic solvent by tangential flow filtration; and (5) optionally freeze-drying the filtrate obtained from the desalting step. The purification method of the prior art reduces the desalting in step b) of the traditional purification method, that is, reduces the number of purification steps, achieves a higher degree of automation and reduces the overall operation time.
[0004] Prior art CN114051499A also improves the conventional oligonucleotide purification method, providing a method for purifying oligonucleotides, the method comprising removing the acid-labile hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide by on-column deprotection with acid. The prior art oligonucleotide purification method avoids step c) in the conventional purification method.
[0005] The above-mentioned prior arts CN112771062A and CN114051499A both mention that it is necessary to remove the hydroxyl protecting group at the 5'-O-terminus of the acid-labile oligonucleotide under acidic conditions. In this process, the oligonucleotide needs to be kept under acidic conditions for a long time. If the oligonucleotide is kept under acidic conditions for a long time, depurination byproducts will be produced (see, "An Acid-Free Deprotection of 5'-Amino-Modified Oligonucleotides", Richard L. Redman, et.al., Org. Process Res. Dev. 2023, 27, 2160-2164).
[0006] Therefore, it is very necessary to develop a purification method that can effectively remove the hydroxyl protecting group at the 5'-O-terminus of oligonucleotides and is efficient, stable, and suitable for large-scale commercial processes. Summary of the invention
[0007] The invention provides a method for purifying an oligonucleotide, comprising the steps of using pure water at 40°C to 60°C for tangential flow filtration to remove a hydroxyl protecting group at the 5'-O-terminal of the oligonucleotide, wherein the hydroxyl protecting group at the 5'-O-terminal is selected from 4,4'-dimethoxytrityl, 4-methoxytrityl or trityl.
[0008] In another more preferred embodiment, the hydroxyl protecting group at the 5'-O-terminus is selected from 4,4'-dimethoxytrityl.
[0009] In another more preferred embodiment, the temperature of the pure water is 45°C to 55°C. In another more preferred embodiment, the temperature of the pure water is 50°C.
[0010] In another preferred embodiment, the tangential flow filtration is performed at a transmembrane pressure of 0.5 bar to 3.5 bar.
[0011] In another preferred embodiment, the tangential flow filtration is carried out at 5 L / h / m 2 ~450L / h / m 2 The flux rate is carried out.
[0012] In another preferred embodiment, the molecular weight cutoff of the membrane used for tangential flow filtration is ≤5KDa. In another more preferred embodiment, the molecular weight cutoff of the membrane used for tangential flow filtration is 1KDa to 3KDa. In another more preferred embodiment, the molecular weight cutoff of the membrane used for tangential flow filtration is 1KDa to 2KDa.
[0013] In another preferred embodiment, the method for purifying oligonucleotides further comprises the step of purifying the crude oligonucleotides obtained after resin cleavage and phosphate deprotection by reverse phase high performance liquid chromatography or anion exchange chromatography before tangential flow filtration.
[0014] In another more preferred embodiment, the method for purifying oligonucleotides further comprises the step of purifying the crude oligonucleotides obtained after resin cleavage and phosphate deprotection using a reverse phase chromatography column before tangential flow filtration.
[0015] In another preferred embodiment, the method for purifying oligonucleotides further comprises the step of freeze-drying the retentate obtained by tangential flow filtration to obtain the target oligonucleotide.
[0016] In another preferred embodiment, the method for purifying oligonucleotides further comprises the steps of: washing the retentate obtained by tangential flow filtration with pure water or a mixture of pure water and an organic solvent, and then freeze-drying the retentate to obtain the target oligonucleotide.
[0017] In another preferred embodiment, in the oligonucleotide purification method, the oligonucleotide is a DNA or RNA with a length of 16-40 nucleotides.
[0018] In another preferred embodiment, in the oligonucleotide purification method, the nucleotide sequence of the oligonucleotide is as shown in SEQ ID NO.1. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The reverse phase chromatography column purification spectrum of the crude oligonucleotide (whose nucleotide sequence is SEQ ID NO.1) is shown. The test results show that the impurities without protecting groups and the product fractions containing protecting groups can be separated, and the purified product fractions have a high purity, which provides a powerful condition for subsequent processing.
[0020] Figure 2 Shown is the UPLC spectrum of the oligonucleotide (whose nucleotide sequence is SEQ ID NO.1) after purification by a reverse phase chromatography column. From the UPLC spectrum, it can be seen that the product purified by reverse phase column chromatography does not contain impurities of deprotected groups, and the purity of the final product containing protective groups is relatively high (the two peaks in the figure are isomer peaks, both of which are target oligonucleotides).
[0021] Figure 3The UPLC chart of the oligonucleotide (whose nucleotide sequence is SEQ ID NO.1) purified by reverse phase chromatography column after tangential flow filtration using 50°C pure water is shown. From the chart, it can be seen that the hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide is completely removed, and no obvious impurity peak appears, indicating that the method of removing the hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide of the present invention is more gentle and does not generate new impurities. DETAILED DESCRIPTION
[0022] Tangential flow filtration is a pressure-driven membrane separation process based on molecular size, which is commonly used for desalting oligonucleotides. The prior art introduces an acidic buffer solution into the tangential flow filtration to remove the hydroxyl protecting group at the end of the 5'-O-oligonucleotide of the oligonucleotide. Although it can reduce the purification steps and shorten the process time, when the oligonucleotide is exposed to an acidic environment for a long time, it will cause depurination reaction, especially in the RNA group. After in-depth research, the inventors of the present application found that the crude oligonucleotide obtained after resin cleavage and phosphate deprotection is purified by reverse phase high performance liquid chromatography or anion exchange chromatography, and the thermal instability of the hydroxyl protecting group at the end of the 5'-O-oligonucleotide is utilized. During the tangential flow filtration process, ultrafiltration is performed using 45-55°C pure water, and desalting is performed while removing the 5'-hydroxyl protecting group. This not only avoids the production of depurination byproducts that may be caused by the oligonucleotide being in an acidic environment for a long time, but also does not require the introduction of a neutralization step. The purification process is efficient and suitable for oligonucleotide purification in large-scale commercial processes.
[0023] During tangential flow filtration, the feed passes through the filter membrane under positive pressure relative to the permeate side (tangentially). A portion of the material smaller than the membrane pore size passes through the membrane as permeate or filtrate, and all other substances are retained on the feed side of the membrane as retentate (also called "retentate"). During the purification of the oligonucleotides of the present invention, the fraction obtained after purification by the reverse phase chromatography column is filtered through tangential flow, and the target oligonucleotide is used as the retentate, and the removed 5'-O-terminal hydroxyl protecting group fragments and inorganic salts pass through the filter membrane. Suitable membranes are commercially available, such as PelliconTM, Omega TM ,or,
[0024] In the description of the present invention, "DMT" refers to a trityl group or its derivatives. For example, 4,4'-dimethoxytrityl is a very effective group for protecting hydroxyl, amino, thiol, etc. It has the advantages of mild reaction conditions, high yield, and stable protecting groups during the reaction process. It has been widely used, especially in the selective protection of multifunctional compounds. The trityl group or its derivatives are unstable in themselves and are easily removed under acidic or high temperature conditions. At present, this type of protecting group is mainly removed by acid, and domestic research is mainly focused on the application of specific compounds. There is a lack of systematic research on this type of protecting group, especially new protection and deprotection methods. Therefore, the present invention mainly provides a new method for removing this type of protecting group under acid-free conditions. This method can be applied to most oligonucleotide drugs containing this type of protecting group.
[0025] In the description herein, an "oligonucleotide" is a polynucleotide molecule consisting of 10 to 40 nucleotide molecules.
[0026] In some specific embodiments of the present invention, before tangential flow filtration using pure water at 40° C. to 60° C., the crude oligonucleotide obtained after resin cleavage and phosphate deprotection is purified using a reverse phase chromatography column, comprising the following steps:
[0027] a) loading a solution of crude oligonucleotides onto a reverse phase chromatography column;
[0028] b) equilibrate the reverse phase chromatography column with a sodium acetate methanol-water buffer solution;
[0029] c) washing the impurities with a sodium acetate methanol-water buffer solution;
[0030] d) eluting the undeprotected oligonucleotide with a sodium acetate methanol-water buffer solution;
[0031] e) cleaning the chromatography column with a sodium acetate methanol buffer solution;
[0032] f) The reverse phase chromatography column is equilibrated with a sodium acetate methanol-water buffer solution.
[0033] The pH value of the crude oligonucleotide solution loaded onto the reverse phase chromatography column is 7.0-10.0, more preferably 7.5-9.0.
[0034] Wherein, the total oligonucleotide content of the solution loaded onto the reverse phase chromatography column is 100-800 OD / mL, more preferably 400-700 OD / mL.
[0035] Furthermore, in step b), the volume content of methanol in the sodium acetate methanol-water buffer solution used to balance the reverse phase chromatography column is 10% to 35%, more preferably, 15% to 25%, and the concentration of sodium acetate is 0.2M.
[0036] Furthermore, in step b), the volume of the sodium acetate methanol-water buffer solution used to balance the reverse phase chromatography column is 0.4 to 0.6 column volumes.
[0037] Furthermore, in step c), the volume content of methanol in the buffer solution used for eluting impurities is 20% to 60%, more preferably, 20% to 52%, and the concentration of sodium acetate is 0.2M.
[0038] Further, in step c), the volume of the sodium acetate methanol-water buffer solution used to elute the impurities is 3 to 4 column volumes.
[0039] Furthermore, in step d), the volume content of methanol in the buffer solution used to elute the undeprotected oligonucleotide is 52% to 80%, more preferably, 52% to 77%, and the concentration of sodium acetate is 0.2M.
[0040] Furthermore, in step d), the volume of the buffer solution used to clean the chromatography column is 7 to 8 column volumes.
[0041] Furthermore, in step e), the volume content of methanol in the sodium acetate methanol-water buffer solution used for cleaning the reverse phase chromatography column is 90% to 100%, more preferably, 95% to 100%, and the concentration of sodium acetate is 0.2M.
[0042] Furthermore, in step e), the volume of the sodium acetate methanol-water buffer solution used to balance the reverse phase chromatography column is 1 to 2 column volumes.
[0043] Furthermore, in step f), the volume content of methanol in the sodium acetate methanol-water buffer solution used to balance the reverse phase chromatography column is 10% to 35%, more preferably, 20% to 30%, and the concentration of sodium acetate is 0.2M.
[0044] Furthermore, in step f), the volume of the sodium acetate methanol-water buffer solution used to balance the reverse phase chromatography column is 1 to 2 column volumes.
[0045] Reverse phase chromatography (RP) purification is a purification method that improves the purity of samples by using the polarity differences of different components in the sample. Crude oligonucleotide samples contain DMT-off impurities and DMT-on samples, which have a large difference in polarity. The DMT-off impurities have a large polarity and a weak retention capacity on the reverse phase chromatography column; the DMT-on samples have a small polarity and a strong retention capacity on the reverse phase chromatography column. The DMT-on oligonucleotide samples were purified using a reverse phase purification sodium acetate methanol system, which can effectively remove the DMT-off impurities. The purified fractions reached a liquid phase purity of more than 97%, providing favorable conditions for subsequent processing.
[0046] In some embodiments of the present invention, the oligonucleotides are subjected to tangential flow filtration comprising the following steps:
[0047] The hydroxyl protecting group at the end of the 5'-O-oligonucleotide of the oligonucleotide is removed by tangential flow filtration using pure water at 40° C. to 60° C., wherein the hydroxyl protecting group is selected from 4,4'-dimethoxytrityl, 4-methoxytrityl or trityl.
[0048] In the process of selecting the temperature of pure water used for tangential flow filtration, on the one hand, the temperature that the filter membrane can withstand is considered, and on the other hand, the temperature required to remove the hydroxyl protecting group at the end of the 5'-O-oligonucleotide is considered. Too high a temperature will damage the filter membrane, and too low a temperature will not effectively remove the DMT hydroxyl protecting group from the 5'-O-end of the oligonucleotide. In some preferred embodiments of the present invention, the temperature of pure water used for tangential flow filtration is 45°C to 55°C.
[0049] During tangential flow filtration, the transmembrane pressure is selected according to the pressure and filtration efficiency of the filter membrane used. Too high a transmembrane pressure will damage the filter membrane, and too low a transmembrane pressure will result in low filtration efficiency. Tangential flow filtration is preferably performed at a transmembrane pressure of 0.5 bar to 3.5 bar, more preferably at a transmembrane pressure of 1.0 bar to 3.0 bar, and even more preferably at a transmembrane pressure of 1.5 bar to 2.5 bar.
[0050] In tangential flow filtration, the flux rate is selected according to the filter membrane used and the filtration efficiency. For a specific filter membrane, if the flux rate is too large, the pressure it bears will increase and the service life will be reduced. If the flux rate is too small, the filtration efficiency will be low. Tangential flow filtration is preferably between 5L / h / m 2 ~450L / h / m 2 The flow rate is preferably between 100 L / h / m 2 ~300L / h / m 2 The flow rate is preferably between 150 L / h / m 2 ~250L / h / m 2The flux rate between them is carried out.
[0051] During tangential flow filtration, the molecular weight cutoff of the filter membrane used is determined according to the molecular weight of the oligonucleotide to be filtered. For the oligonucleotide sequence shown in SEQ ID NO.1, the molecular weight cutoff of the filter membrane used for tangential flow filtration is preferably ≤5KDa, and more preferably 1KDa to 3KDa.
[0052] The oligonucleotide sequence shown in SEQ ID NO.1 is 5'-TCACTTTCATAATGCTGG-3', wherein the 5'-hydroxyl group of the terminal nucleoside has a DMT protecting group, the 2' position of each nucleoside is substituted with MOE (ethoxyethyl), a methyl group is introduced into the 5 position of all cytosine bases, and the non-bonded oxygen in each internucleotide bond is replaced with a sulfur atom. The sequence can also be represented as '5'-DMT-Ts M e CsA Me CsTsTsTs Me CsAsTsAsAsTsGs Me CsTsGsG-3'.
[0053] In some preferred embodiments of the present invention, the retentate obtained by tangential flow filtration can be directly freeze-dried to obtain the target oligonucleotide product, because the removal of the hydroxyl protecting group at the 5'-O-terminus and desalting are carried out simultaneously during the tangential flow filtration process, and the obtained retentate contains only the target oligonucleotide and does not contain other impurities (such as organic matter (DMT fragments) and inorganic salts generated by the removed hydroxyl protecting group). In some preferred embodiments of the present invention, in order to obtain a target oligonucleotide with better purity, the retentate obtained by tangential flow filtration can be first washed with pure water or a mixture of pure water and an organic solvent to further remove the inorganic salts and DMT fragments therein, and then freeze-dried to obtain the target oligonucleotide. When the retentate obtained by tangential flow filtration is washed with a mixture of pure water and an organic solvent, it is first washed with a mixture of pure water and an organic solvent, and finally washed with pure water, so that the residual amount of organic solvent in the retentate is as small as possible. The organic solvent is preferably an alcohol, such as methanol, ethanol or isopropanol, more preferably ethanol. The volume ratio of water to organic solvent is preferably 1 to 5:1.
[0054] Freeze drying is a technique known to those skilled in the art. The purification process of the oligonucleotides of the present invention is carried out according to conventional freeze drying operations for oligonucleotides in the art.
[0055] Compared with the prior art, the beneficial effects of the present invention are:
[0056] The present invention utilizes 50° C. to 60° C. purified water for tangential flow filtration, and simultaneously removes the hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide and the salt in the system, which not only avoids the generation of depurination byproducts that may be caused by the oligonucleotide being in an acidic environment for a long time, but also does not require the introduction of a neutralization step, and the process is efficient and suitable for oligonucleotide purification in large-scale commercial processes.
[0057] The present invention will be further described below in conjunction with specific implementation. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the following examples are usually based on normal conditions. Unless otherwise stated, percentages and parts are calculated by weight.
[0058] In the following examples, unless otherwise specified, the concentrations are by mass.
[0059] abbreviation:
[0060] MOE=2-methoxyethyl
[0061] NMI = N-methylimidazole
[0062] PADS = phenylacetyl disulfide
[0063] Tol = Toluene
[0064] A = Adenosine
[0065] T = thymidine
[0066] Me C=5-methylcytidine
[0067] G = Guanosine
[0068] DCA = dichloroacetic acid
[0069] DCI = 4,5-dicyanoimidazole
[0070] DEA = Diethylamine
[0071] ACN = acetonitrile
[0072] Ac2O = acetic anhydride
[0073] CV = column volume
[0074] Example 1
[0075] (1) 5'-DMT-Ts Me CsA Me CsTsTsTs Me CsAsTsAsAsTsGs Me The target compound for the synthesis of CsTsGsG-3' was used Oligopilot plus 100 was synthesized as "DMT-on" on a 2 mmol scale
[0076] X = 2'-MOE nucleoside; "s" represents a phosphorothioate bond;
[0077] The target compound DMT is 4,4'-dimethoxytrityl,
[0078] The synthesis parameters are shown in Table 1 below.
[0079] Table 1
[0080]
[0081] (2) Reverse chromatography column purification procedure: The crude oligonucleotide solution at pH = 8.0 after concentrated ammonia was loaded onto an anion exchange column (having a PolyRP-300 column medium, an inner diameter of 2.12 cm, a column height of about 25 cm, and a column volume of about 88 mL) to achieve a column load of about 470 OD / mL. The purification equipment used was Pure 150. Once the crude oligonucleotide is loaded onto the reverse phase chromatography column, it is equilibrated with 0.53 column volumes (CV) of 20% (v / v) 0.2M sodium acetate methanol-water solution, and after equilibration, it is gradient eluted to 52% B phase with 3.76 CV of 0.2M sodium acetate methanol-water solution, and then gradient eluted to 77% B phase with 7.85 CV of 0.2M sodium acetate methanol-water solution to obtain a refined undeprotected oligonucleotide sample, and then the column is washed with 1.5 CV of 100% 0.2M sodium acetate methanol solution, and finally the column is equilibrated with 1.5 CV of 0.2M sodium acetate methanol-water solution containing less than 20% methanol.
[0082] The reverse phase chromatography purification conditions are shown in Table 2 below.
[0083] Table 2
[0084]
[0085] (3) Tangential flow filtration procedure: The fractions from the reverse phase chromatography (RP) column purification were collected to obtain 163 mL (4.82 mg / mL) of oligonucleotide solution. 2 )of The material was processed on a Flux S machine, using 50°C pure water for desalination, and DMT was removed during desalination (the hydroxyl protecting group (DMT) at the 5'-O-terminus was unstable at this temperature). The 50°C was set according to the temperature of the membrane package used for tangential flow filtration, and a higher temperature would damage the membrane package. The tangential flow filtration program parameters are described in detail in Table 3 below.
[0086] Table 3 Parameters of Flux S
[0087]
[0088] During the tangential flow filtration process, the removal of the hydroxyl protecting group (DMT) at the 5'-O-terminus was monitored, as shown in Table 4 below.
[0089] Table 4
[0090]
[0091]
[0092] From the DMT-ON content, DMT-off content and permeate conductivity (reaction salt removal) in Table 4, it can be seen that under this condition, after 6.5 hours of tangential flow filtration, the hydroxyl protecting group at the 5'-O-terminus of the oligonucleotide is basically completely removed, and the salt is also basically completely removed.
[0093] The retentate obtained by tangential flow filtration was freeze-dried to obtain 6.4 g of the desired product (45% overall yield based on synthetic scale, 99% UV purity).
[0094] Lower temperatures (eg, 48° C., 45° C., 40° C., etc.) are also feasible, but the tangential flow filtration time needs to be increased to completely remove the hydroxyl protecting group at the 5′-O-terminus.
[0095] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A method for purifying oligonucleotides, characterized in that: The method comprises using pure water at 40° C. to 60° C. to perform tangential flow filtration to remove the hydroxyl protecting group at the 5'-O-terminal of the oligonucleotide, wherein the hydroxyl protecting group at the 5'-O-terminal is selected from 4,4'-dimethoxytrityl, 4-methoxytrityl or trityl.
2. The method for purifying oligonucleotide according to claim 1, characterized in that: The hydroxyl protecting group at the 5'-O-terminal end is selected from 4,4'-dimethoxytrityl.
3. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The temperature of the pure water is 45°C to 55°C, more preferably, 50°C.
4. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The tangential flow filtration is carried out at a transmembrane pressure of 0.5 bar to 3.5 bar, and / or The tangential flow filtration was carried out at 5 L / h / m 2 ~450L / h / m 2 The flux rate is carried out.
5. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The molecular weight cutoff of the membrane used for the tangential flow filtration is ≤5KDa, more preferably, the molecular weight cutoff of the membrane used is 1KDa to 3KDa, most preferably, the molecular weight cutoff of the membrane used is 1KDa to 2KDa.
6. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The method further comprises the step of purifying the crude oligonucleotide obtained after resin cleavage and phosphate deprotection by reverse phase high performance liquid chromatography or anion exchange chromatography before tangential flow filtration.
7. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The method further comprises the following steps: freeze-drying the retentate obtained by tangential flow filtration to obtain the target oligonucleotide.
8. The method for purifying oligonucleotide according to claim 1 or 2, characterized in that: The method further comprises the following steps: washing the retentate obtained by tangential flow filtration with pure water or a mixture of pure water and an organic solvent, and then freeze-drying the retentate to obtain the target oligonucleotide. 9 . The method for purifying an oligonucleotide according to claim 1 , wherein the oligonucleotide is a DNA or RNA with a length of 16 to 40 nucleotides.
10. The method for purifying an oligonucleotide according to any one of claims 1 to 8, wherein the nucleotide sequence of the oligonucleotide is as shown in SEQ ID NO.1.
